(Journal of Allergy and Clinical Immunology, 2002;109:251-256)
2ÔÂ21ÈÕ(IvanhoeÐÂÎÅרÏß)¾ÝÒ»ÏîеÄÑо¿·¢ÏÖ£¬ÍÑÃô×¢Éä¿Éʹ¶ùͯ·¢ÉúÏø´µÄ»úÂʼõÉÙÒ»°ë¡£
ΪÁ˽âÍÑÃô×¢ÉäÁÆ·¨¶ÔÔ¤·ÀÏø´µÄ×÷Óã¬Å·ÖÞµÄÁù¸ö¶ù¿ÆÖÐÐÄÔÚÒ»Ïî´ó¹æÄ£¶àÖÐÐÄÑо¿ÖзÖÎöÁË200¶àÃûÏø´»¼¶ùµÄ×ÊÁÏ¡£ÆäÖÐÒ»×é¶ùͯ½ÓÊÜÒ©ÎïÖÎÁƹýÃôÖ¢×´£¬ÁíÍâÒ»×é¶ùͯ½ÓÊÜÒ©ÎïºÍÍÑÃô×¢ÉäÖÎÁÆ¡£
¾¹ýÈýÄêµÄÖÎÁÆ£¬Ã»ÓнÓÊÜÍÑÃô×¢ÉäµÄ¶ùͯÓÐ44%·¢Õ¹ÎªÇá¶ÈÏø´£¬¶ø½ÓÊÜÍÑÃô×¢ÉäµÄ¶ùͯ·¢ÉúÇá¶ÈÏø´µÄ½öÓÐ24%¡£¿ÆÑÐÈËԱͬʱҲ·¢ÏÖÍÑÃô×¢Éä¿É¼õÇáÊÜÊÔÕߵįøµÀÑ×Ö¢ºÍ±ä̬·´Ó¦Ö¢×´¡£
ŦԼÊÐʥ·¼Ó-ÂÞ˹¸£Ò½ÔºµÄIra Finegold²©Ê¿Ö¸³ö£¬¡°¸ÃÑо¿Ö¤ÊµÁËÎÒÃǵĹ۵㣬¼´ÍÑÃô×¢ÉäʹÓ÷¶Î§Ô½¹ã£¬î¾»¼Ïø´²¡µÄ¶ùͯ¾Í»áÔ½ÉÙ¡£ÎÒÃÇÒ²½¨ÒéÓйýÃôÌåÖʵĸöÌåÓ¦µ½¹ýÃô֢ר¿ÆÒ½Ê¦´¦½øÐÐÒ»´ÎÏø´¼ì²é£¬¼´Ê¹ËûÃÇÈÏΪ×Ô¼º¿ÉÄܽö½ö»¼ÓпݲÝÈÈÒ²Ó¦Èç´Ë¡£¡±
À´×Ôµ¤ÂóALK-AbelloÑо¿Ð¡×éµÄºÏ×÷ÕßLars Jacobsen²©Ê¿×ܽáµÀ£¬¡°ÎÒÃǵÄÑо¿×ÊÁÏ֤ʵÁËÃâÒßÁÆ·¨µÄÔ¤·À¼ÛÖµ¡£ÕâÊÇĿǰ½öÓеĿÉÓÃÀ´×è¶ÏÒýÆð±ä̬·´Ó¦»ù±¾ÉúÀí»úÖÆµÄÓÐЧÖÎÁÆ·½·¨¡£¡±
ÔÚÃÀ¹úÓÐ1,700ÍòÈË»¼ÓкôÎüµÀÂýÐÐÑ×Ö¢»òÏø´¡£Ïø´¿ÉÒýÆð´Ãù¡¢¿ÈËÔ¡¢Ðز¿½ôÆÈ¸ÐºÍºôÎü¼±´Ù¡£¾ÝÃÀ¹ú±ä̬·´Ó¦¡¢Ïø´ºÍÃâÒßѧлáµÄ×ÊÁÏÏÔʾ£¬±ä̬·´Ó¦¿ÉÒýÆð80%µÄ¶ùÍ¯Ïø´ºÍ50%µÄ³ÉÈËÏø´·¢²¡¡£ (ÎÄÕ³ö´¦£ºÒ½Ñ§¿Õ¼ä)
2ÔÂ21ÈÕ(IvanhoeÐÂÎÅרÏß)¾ÝÒ»ÏîеÄÑо¿·¢ÏÖ£¬ÍÑÃô×¢Éä¿Éʹ¶ùͯ·¢ÉúÏø´µÄ»úÂʼõÉÙÒ»°ë¡£
ΪÁ˽âÍÑÃô×¢ÉäÁÆ·¨¶ÔÔ¤·ÀÏø´µÄ×÷Óã¬Å·ÖÞµÄÁù¸ö¶ù¿ÆÖÐÐÄÔÚÒ»Ïî´ó¹æÄ£¶àÖÐÐÄÑо¿ÖзÖÎöÁË200¶àÃûÏø´»¼¶ùµÄ×ÊÁÏ¡£ÆäÖÐÒ»×é¶ùͯ½ÓÊÜÒ©ÎïÖÎÁƹýÃôÖ¢×´£¬ÁíÍâÒ»×é¶ùͯ½ÓÊÜÒ©ÎïºÍÍÑÃô×¢ÉäÖÎÁÆ¡£
¾¹ýÈýÄêµÄÖÎÁÆ£¬Ã»ÓнÓÊÜÍÑÃô×¢ÉäµÄ¶ùͯÓÐ44%·¢Õ¹ÎªÇá¶ÈÏø´£¬¶ø½ÓÊÜÍÑÃô×¢ÉäµÄ¶ùͯ·¢ÉúÇá¶ÈÏø´µÄ½öÓÐ24%¡£¿ÆÑÐÈËԱͬʱҲ·¢ÏÖÍÑÃô×¢Éä¿É¼õÇáÊÜÊÔÕߵįøµÀÑ×Ö¢ºÍ±ä̬·´Ó¦Ö¢×´¡£
ŦԼÊÐʥ·¼Ó-ÂÞ˹¸£Ò½ÔºµÄIra Finegold²©Ê¿Ö¸³ö£¬¡°¸ÃÑо¿Ö¤ÊµÁËÎÒÃǵĹ۵㣬¼´ÍÑÃô×¢ÉäʹÓ÷¶Î§Ô½¹ã£¬î¾»¼Ïø´²¡µÄ¶ùͯ¾Í»áÔ½ÉÙ¡£ÎÒÃÇÒ²½¨ÒéÓйýÃôÌåÖʵĸöÌåÓ¦µ½¹ýÃô֢ר¿ÆÒ½Ê¦´¦½øÐÐÒ»´ÎÏø´¼ì²é£¬¼´Ê¹ËûÃÇÈÏΪ×Ô¼º¿ÉÄܽö½ö»¼ÓпݲÝÈÈÒ²Ó¦Èç´Ë¡£¡±
À´×Ôµ¤ÂóALK-AbelloÑо¿Ð¡×éµÄºÏ×÷ÕßLars Jacobsen²©Ê¿×ܽáµÀ£¬¡°ÎÒÃǵÄÑо¿×ÊÁÏ֤ʵÁËÃâÒßÁÆ·¨µÄÔ¤·À¼ÛÖµ¡£ÕâÊÇĿǰ½öÓеĿÉÓÃÀ´×è¶ÏÒýÆð±ä̬·´Ó¦»ù±¾ÉúÀí»úÖÆµÄÓÐЧÖÎÁÆ·½·¨¡£¡±
ÔÚÃÀ¹úÓÐ1,700ÍòÈË»¼ÓкôÎüµÀÂýÐÐÑ×Ö¢»òÏø´¡£Ïø´¿ÉÒýÆð´Ãù¡¢¿ÈËÔ¡¢Ðز¿½ôÆÈ¸ÐºÍºôÎü¼±´Ù¡£¾ÝÃÀ¹ú±ä̬·´Ó¦¡¢Ïø´ºÍÃâÒßѧлáµÄ×ÊÁÏÏÔʾ£¬±ä̬·´Ó¦¿ÉÒýÆð80%µÄ¶ùÍ¯Ïø´ºÍ50%µÄ³ÉÈËÏø´·¢²¡¡£ (ÎÄÕ³ö´¦£ºÒ½Ñ§¿Õ¼ä)